Opioid Analgesics — Pharmacology and Toxicology

Mechanism of Analgesic Action

• Opioid agonists bind to μ-receptors on nociceptive neurons in the dorsal horn of the spinal cord, inhibiting the release of excitatory neurotransmitters (substance P, glutamate) and hyperpolarizing neurons via activation of inwardly-rectifying K+ channels
• μ-receptors in the brainstem (rostroventral medulla, locus coeruleus) activate descending inhibitory pain pathways via monoaminergic systems (norepinephrine and serotonin)
• Binding to μ-receptors in the periaqueductal gray and other limbic structures modulates emotional responses to pain
• The result is selective depression of nociceptive transmission while motor function and touch sensation remain relatively intact

Molecular Basis of Central Nervous System Effects

• μ-receptor activation in the brainstem and chemoreceptor trigger zone produces respiratory depression through direct inhibition of respiratory centers and reduced CO2 chemoreceptor sensitivity; this is the primary cause of opioid overdose deaths
• κ-receptors in the nucleus accumbens and limbic system mediate dysphoric effects but also contribute to analgesia
• δ-receptors modulate pain perception and reward but have limited clinical utility
• Activation of μ-receptors in the ventral tegmental area and nucleus accumbens produces dopamine release, explaining the euphoric effects and addiction liability
• Opioid-induced physical dependence results from chronic receptor activation leading to homeostatic downregulation of receptor signaling and upregulation of opposing systems (e.g., increased adenylyl cyclase activity); abrupt discontinuation causes withdrawal as these compensatory mechanisms persist without drug-induced suppression

Gastrointestinal and Other Peripheral Effects

• Opioid receptors on myenteric and submucosal plexuses of the GI tract cause decreased peristalsis, increased sphincter tone, and constipation (a nearly universal side effect)
• μ-receptors in the chemoreceptor trigger zone produce nausea and vomiting, particularly with first doses or rapid escalation
• Activation of μ-receptors on mast cells triggers histamine release, causing itching, flushing, and bronchospasm in susceptible individuals
• Opioids cause miosis (pinpoint pupils) via direct action on oculomotor nuclei, mediated by both central and peripheral mechanisms; this is characteristic of overdose
• Opioid-induced immunosuppression may occur through receptor-mediated effects on T-cell proliferation and NK cell activity, potentially increasing infection risk with chronic use

Pharmacokinetic Considerations

• First-pass metabolism is significant for many opioids (morphine, codeine) when taken orally, explaining why oral doses are 3-6 times higher than parenteral doses; fentanyl is highly lipophilic and crosses the blood-brain barrier rapidly
• Metabolic pathways vary: morphine undergoes glucuronidation to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active, contributes to analgesia and toxicity); codeine is demethylated to morphine via CYP2D6; oxycodone and hydrocodone are metabolized by CYP3A4; fentanyl is metabolized by CYP3A4
• Lipophilicity determines CNS penetration and duration: morphine is hydrophilic (slower onset, longer duration); fentanyl is highly lipophilic (rapid onset, short duration); methadone is lipophilic with very long half-life
• Organ-dependent elimination: renal excretion is important for morphine and its active metabolites (risk of accumulation in renal failure); hepatic disease impairs metabolism of all opioids

Primary Indications for Opioid Use

• Moderate to severe acute pain (postoperative, trauma, acute MI): opioids are indicated when non-opioid analgesics are insufficient; acute pain typically requires short-term use (days to weeks)
• Cancer pain: opioids are essential for cancer patients; escalating doses are necessary as disease progresses, and tolerance development is expected and managed through dose adjustment
• Chronic pain conditions: chronic non-cancer pain management with opioids remains controversial; long-term efficacy is unproven, and risks may outweigh benefits in many patients; current guidelines recommend opioids only after failure of non-opioid approaches
• Palliative and end-of-life care: high-dose opioids are appropriate for terminal patients where respiratory depression is not a limiting factor

Risk Factors for Adverse Outcomes and Addiction

• Personal history of substance use disorder: the strongest predictor of opioid addiction; patients with prior alcohol, benzodiazepine, or other drug use have 5-10 fold higher risk
• Psychiatric comorbidity: depression, anxiety, and PTSD are associated with increased opioid misuse and overdose risk
• Genetic factors: CYP2D6 polymorphisms affect metabolism (poor metabolizers may accumulate active metabolites; ultra-rapid metabolizers may require higher doses); mu-receptor gene variants influence analgesic response
• Age extremes: elderly patients have reduced metabolism and increased CNS sensitivity, requiring lower doses; infants and young children have immature metabolism but are at high risk of accidental poisoning
• Concurrent medications: CYP3A4 and CYP2D6 inhibitors (macrolide antibiotics, antifungals, protease inhibitors) increase opioid levels; benzodiazepines dramatically increase overdose risk through synergistic CNS/respiratory depression
• Hepatic and renal disease: impair metabolism and clearance; renal failure particularly impacts morphine and codeine metabolites
• Respiratory disease: patients with COPD, sleep apnea, or other causes of baseline hypercapnia are at high risk for opioid-induced respiratory depression
• Environmental factors: high rates of substance use disorder in patients' social networks, easy access to drugs, and previous negative life events predict addiction

Pain Relief and Analgesic Effects

• Reduction in pain intensity and affective component of pain: patients report both decreased pain sensation and improved mood/ability to cope with pain within 30 minutes of IV dosing or 1 hour of oral dosing
• The analgesic effect is dose-dependent but shows a ceiling effect at higher doses for some opioids (partial agonists); pure mu-agonists do not have a ceiling for analgesia, but respiratory depression increases linearly with dose

Central Nervous System Effects

• Sedation and drowsiness: common with initial dosing, may improve with tolerance; mediated by mu-receptors in the brainstem and cortex
• Euphoria or dysphoria: mu-receptor activation in the ventral tegmental area produces euphoria (reward) in naive users, driving addiction liability; some patients experience dysphoria, particularly with kappa-agonist activity
• Respiratory depression: decreased respiratory drive, reduced tidal volume, and decreased CO2 chemoreceptor sensitivity; begins at low doses but worsens with higher doses and is potentiated by concurrent CNS depressants
• Miosis (pinpoint pupils): pathognomonic finding in opioid overdose or acute intoxication; mediated by oculomotor nuclei
• Cognitive impairment: decreased alertness, impaired concentration, and slowed reaction time; particularly concerning in elderly patients and those operating machinery

Gastrointestinal Effects

• Nausea and vomiting: occurs in 20-30% of patients, often with initial doses; mediated by chemoreceptor trigger zone activation; tends to improve with continued use as tolerance develops
• Constipation: nearly universal with chronic opioid use; results from decreased peristalsis and increased sphincter tone; does not develop tolerance and is the most common limiting side effect of chronic therapy
• Decreased appetite: common subjective complaint, may contribute to weight loss
• Biliary colic: opioid-induced increase in biliary sphincter tone can provoke pain in patients with biliary disease, particularly with morphine

Other Physical Findings

• Histamine release reactions: flushing, pruritus, urticaria, and bronchospasm, particularly with morphine and codeine; non-histamine-releasing opioids (fentanyl) may be better tolerated
• Peripheral edema: uncommon but reported with chronic use, possibly related to immune or cardiovascular effects
• Hormonal effects: decreased testosterone, increased prolactin, and impaired sexual function with chronic high-dose opioid use
• Myosis severity: differs by opioid type and route; IV heroin produces maximal miosis; this sign distinguishes opioid overdose from other causes of altered mental status

Manifestations of Tolerance and Physical Dependence

• Tolerance: progressive decrease in drug effect requiring increasing doses to maintain the same analgesic/euphoric response; develops at different rates for different effects (analgesia and respiratory depression may tolerate at different rates, a dangerous pharmacodynamic property)
• Withdrawal syndrome: begins 6-12 hours after last dose of short-acting opioids (morphine, heroin) or 24-48 hours for long-acting agents (methadone); includes mydriasis (opposite of intoxication), lacrimation, rhinorrhea, yawning, diaphoresis, piloerection ("goosebumps"), anxiety, irritability, insomnia, muscle aches, nausea, vomiting, diarrhea, and hyperreflexia; not life-threatening but extremely uncomfortable

Clinical Assessment of Opioid Use and Overdose

• History and presentation: acute or chronic opioid use is typically obtained by direct questioning in pain assessment; in overdose, collateral history from emergency responders, family, or bystanders is valuable; the classic triad of depressed mental status, respiratory depression, and miosis should raise suspicion for opioid overdose
• Urine drug screening (UDS): detects opioids and semi-synthetic derivatives (oxycodone, hydrocodone) but not synthetic opioids like fentanyl or tramadol on standard immunoassay screens; immunoassay has ~90% sensitivity and specificity; gas chromatography/mass spectrometry (GC-MS) is the confirmatory gold standard and can detect all opioids; timing matters—morphine is detectable 2-48 hours after use, longer in urine than blood
• Serum and urine morphine/opioid levels: not routinely available but can be ordered; serum levels do not correlate well with clinical effects due to tolerance; provide supportive evidence but are not diagnostic of overdose on their own; therapeutic morphine levels are typically <2 mg/L, but overdose can occur at lower levels in opioid-naive individuals
• Blood gas analysis: in overdose, reveals hypoxemia, hypercarbia (elevated CO2), and respiratory acidosis reflecting hypoventilation; PaO2 <60 mmHg and PaCO2 >45 mmHg indicate significant respiratory depression
• Naloxone test/challenge: intravenous naloxone (0.4-2 mg) is both diagnostic and therapeutic; rapid reversal of respiratory depression, miosis, and altered mental status within seconds to 2 minutes confirms opioid-mediated effects; failure to respond may indicate non-opioid overdose or other causes of coma
• Imaging studies: chest X-ray may reveal pulmonary edema, a common finding in opioid overdose (likely related to opioid-induced pulmonary capillary leak); head CT is indicated if altered mental status is disproportionate to opioid dose or if head trauma is suspected

Diagnostic Criteria and Scoring Systems

• DSM-5 criteria for Opioid Use Disorder: requires 2 of 11 criteria including tolerance, withdrawal, unsuccessful attempts to control use, continued use despite harm, and social/occupational impairment; diagnosis is based on behavioral and psychological features rather than laboratory tests
• OARRS (Opioid Analgesic Risk Reduction System) and SOAPP-R (Screener and Opioid Assessment for Patients with Pain—Revised): validated instruments to assess risk of opioid misuse in chronic pain patients; scores above certain thresholds suggest higher risk and warrant closer monitoring or alternative management
• Clinical Opiate Withdrawal Scale (COWS): a scored assessment tool for severity of withdrawal syndrome; scores >5-8 indicate mild withdrawal, >13 moderate, >24 moderately severe, >36 severe; useful for titrating methadone or buprenorphine during detoxification
• Respiratory depression severity: depends on context; normal respiratory rate is 12-20 breaths/min; depression is typically defined as <12 breaths/min or end-tidal CO2 >45 mmHg; severe respiratory depression with apnea and cyanosis requires immediate intervention

Differential Diagnosis

• Other causes of altered mental status with miosis: pontine hemorrhage (pinpoint pupils without respiratory depression as prominent finding), cholinergic toxicity/organophosphate poisoning (miosis plus excessive secretions and muscle fasciculations), sedative/hypnotic overdose (mental status depression without characteristic pupil findings)
• Respiratory depression from other causes: benzodiazepine or alcohol overdose, pulmonary disease, neuromuscular disorders; the combination with miosis and rapid reversal with naloxone distinguishes opioid overdose

Pain Management with Opioid Analgesics

First-Line Opioids for Acute Pain

• Morphine: the prototypical mu-receptor agonist; IV dosing 0.1 mg/kg every 2-4 hours for acute severe pain; oral dosing 10-30 mg every 4 hours; onset 15-30 minutes IV, 30-60 minutes oral; duration 3-6 hours; first-pass hepatic metabolism limits oral bioavailability (~25%); undergoes glucuronidation to active morphine-6-glucuronide and inactive morphine-3-glucuronide; risk of accumulation in renal failure
• Fentanyl: synthetic opioid 50-100 times more potent than morphine; IV dose 1-2 mcg/kg for acute pain; transdermal patch 12-100 mcg/hour for chronic pain; rapid onset (within minutes IV), short duration (30-60 minutes); extremely lipophilic allowing high CNS penetration; metabolized by CYP3A4; no active metabolites; advantages include rapid onset, no histamine release, and less nausea; transdermal formulation requires careful dosing due to long absorption phase (12-24 hours to steady state) and overdose risk in opioid-naive patients
• Oxycodone: semi-synthetic mu-agonist; oral dosing 5-30 mg every 4-6 hours; similar potency to morphine orally; metabolized by CYP3A4 to noroxycodone (inactive) and CYP2D6 to oxymorphone (active, contributes 5-10% of analgesic effect); extended-release formulation (OxyContin) available for chronic pain; abuse potential higher than morphine due to greater euphoria

Alternative Opioids and Specific Contexts

• Hydrocodone: semi-synthetic; oral dosing 5-10 mg every 4-6 hours; combined with acetaminophen or ibuprofen in many formulations; metabolized to hydromorphone (active) by CYP2D6; considered a Schedule II controlled substance; poor oral bioavailability (25%) limits utility
• **Cod

Dose-limiting and life-threatening toxicities

• Respiratory depression: μ-receptor–mediated blunting of medullary CO2 responsiveness lowers respiratory rate and tidal volume; it is the proximate cause of death in overdose and is markedly potentiated by benzodiazepines, alcohol, gabapentinoids, and sleep-disordered breathing. The FDA carries a boxed warning against routine co-prescription of opioids and benzodiazepines, and the CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain advises avoiding this combination where possible.
• Sedation precedes hypoventilation: monitor a sedation scale plus respiratory rate (capnography in high-risk inpatients) — rising sedation is the earliest warning sign.
• Chest wall/glottic rigidity: seen with rapid high-dose IV fentanyl; impairs bag-mask ventilation and may require naloxone or neuromuscular blockade.
• Noncardiogenic pulmonary edema may follow overdose or rapid reversal.

Agent-specific toxicities

• Meperidine: the metabolite normeperidine accumulates in renal impairment and with repeated dosing, causing tremor, myoclonus, and seizures (naloxone does not reverse this); combined with an MAOI it precipitates serotonin syndrome.
• Methadone: hERG blockade causes QT prolongation and torsades; its long, variable half-life produces delayed accumulation — obtain a baseline and follow-up ECG and titrate slowly.
• Tramadol: lowers seizure threshold and inhibits serotonin/norepinephrine reuptake — serotonin syndrome risk with SSRIs/SNRIs.
• Morphine/codeine: active glucuronide and CYP2D6-derived metabolites accumulate in renal failure; prefer fentanyl or hydromorphone.

• The overdose triad: depressed mental status + respiratory depression + pinpoint pupils. Respiratory rate, not pupil size, is the parameter that kills — a normal-appearing pupil does not exclude opioid toxicity (meperidine and mixed ingestions may spare miosis).
• Single best next step in suspected overdose: support ventilation (bag-mask) and give naloxone, 0.4 mg IV or 4 mg intranasal, titrated to respiratory drive. Because naloxone outlasts neither methadone nor extended-release oxycodone nor many illicit fentanyl analogues, the patient must be observed and often redosed or placed on an infusion — "woke up, discharged from the ED" is a classic wrong answer.
• Common distractor: flumazenil. It reverses benzodiazepines, not opioids, and risks seizures in mixed or chronic-benzodiazepine patients.
• Meperidine + renal failure = seizures via normeperidine; meperidine + MAOI = serotonin syndrome. This is the one association examiners test most about a non-prototype opioid.
• Methadone: QT prolongation and torsades de pointes, plus a long half-life causing delayed, late respiratory depression during titration.
• Codeine is a prodrug requiring CYP2D6 conversion to morphine: ultra-rapid metabolizers (and their breastfed infants) risk fatal toxicity; poor metabolizers get no analgesia. FDA contraindicates codeine and tramadol in children under 12 and after tonsillectomy.
• Tolerance develops to euphoria, sedation, nausea, and respiratory depression — but never to constipation or miosis. Persistent pinpoint pupils in a chronic user are expected; treat constipation with a stimulant laxative such as senna, not with fiber, which can worsen obstruction.
• Withdrawal is miserable but not lethal (contrast with alcohol/benzodiazepine withdrawal): mydriasis, lacrimation, rhinorrhea, piloerection, diarrhea, yawning. For opioid use disorder, the SAMHSA/ASAM guideline favors buprenorphine or methadone over detoxification alone; give buprenorphine only after objective withdrawal (COWS) appears, or it precipitates withdrawal. In pregnancy, ACOG recommends continued buprenorphine or methadone rather than withdrawal management.